Martin den Adel

Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

Dorien Groenendaal‐van de Meent, Martin den Adel, Jan Noukens et al. · Clinical Drug Investigation · 2016 · 38 citations · Full text

Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects

Dorien Groenendaal‐van de Meent, Martin den Adel, Jan van Dijk et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2018 · 23 citations · Full text

Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies

Tomohiro Kusawake, James J. Keirns, Donna Kowalski et al. · Advances in Therapy · 2017 · 21 citations · Full text

The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction Study

Dorien Groenendaal‐van de Meent, Martin den Adel, Sanne Rijnders et al. · Clinical Therapeutics · 2016 · 20 citations

Healthy Volunteers, Hypoxia (Medicine), Pharmacology +4

Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

Dorien Groenendaal‐van de Meent, Virginie Kerbusch, Rüdiger Kaspera et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2020 · 17 citations · Full text